Logo image of ATYR

ATYR PHARMA INC (ATYR) Stock Fundamental Analysis

NASDAQ:ATYR - Nasdaq - US0021202025 - Common Stock - Currency: USD

3.8  +0.05 (+1.33%)

Fundamental Rating

2

Taking everything into account, ATYR scores 2 out of 10 in our fundamental rating. ATYR was compared to 561 industry peers in the Biotechnology industry. While ATYR seems to be doing ok healthwise, there are quite some concerns on its profitability. ATYR is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ATYR has reported negative net income.
ATYR had a negative operating cash flow in the past year.
In the past 5 years ATYR always reported negative net income.
In the past 5 years ATYR always reported negative operating cash flow.
ATYR Yearly Net Income VS EBIT VS OCF VS FCFATYR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of ATYR (-66.12%) is worse than 63.81% of its industry peers.
The Return On Equity of ATYR (-91.44%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -66.12%
ROE -91.44%
ROIC N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ATYR Yearly ROA, ROE, ROICATYR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATYR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATYR Yearly Profit, Operating, Gross MarginsATYR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

ATYR does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ATYR has been increased compared to 1 year ago.
ATYR has more shares outstanding than it did 5 years ago.
ATYR has a better debt/assets ratio than last year.
ATYR Yearly Shares OutstandingATYR Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ATYR Yearly Total Debt VS Total AssetsATYR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

ATYR has an Altman-Z score of -1.72. This is a bad value and indicates that ATYR is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -1.72, ATYR perfoms like the industry average, outperforming 56.51% of the companies in the same industry.
ATYR has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of ATYR (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -1.72
ROIC/WACCN/A
WACC10.11%
ATYR Yearly LT Debt VS Equity VS FCFATYR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 5.48 indicates that ATYR has no problem at all paying its short term obligations.
ATYR has a Current ratio of 5.48. This is comparable to the rest of the industry: ATYR outperforms 59.89% of its industry peers.
ATYR has a Quick Ratio of 5.48. This indicates that ATYR is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.48, ATYR is doing good in the industry, outperforming 60.78% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.48
Quick Ratio 5.48
ATYR Yearly Current Assets VS Current LiabilitesATYR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 10.00% over the past year.
Looking at the last year, ATYR shows a very negative growth in Revenue. The Revenue has decreased by -33.43% in the last year.
Measured over the past years, ATYR shows a very negative growth in Revenue. The Revenue has been decreasing by -11.05% on average per year.
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.09%
Revenue 1Y (TTM)-33.43%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%-100%

3.2 Future

ATYR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.82% yearly.
The Revenue is expected to grow by 383.55% on average over the next years. This is a very strong growth
EPS Next Y23.5%
EPS Next 2Y18.72%
EPS Next 3Y30.51%
EPS Next 5Y41.82%
Revenue Next Year1598.99%
Revenue Next 2Y1408.36%
Revenue Next 3Y782.06%
Revenue Next 5Y383.55%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
ATYR Yearly Revenue VS EstimatesATYR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATYR Yearly EPS VS EstimatesATYR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ATYR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ATYR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATYR Price Earnings VS Forward Price EarningsATYR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATYR Per share dataATYR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

ATYR's earnings are expected to grow with 30.51% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y18.72%
EPS Next 3Y30.51%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATYR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATYR PHARMA INC

NASDAQ:ATYR (5/22/2025, 12:19:30 PM)

3.8

+0.05 (+1.33%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners66.44%
Inst Owner ChangeN/A
Ins Owners2.18%
Ins Owner Change8.22%
Market Cap337.67M
Analysts83.53
Price Target19.06 (401.58%)
Short Float %13.46%
Short Ratio8.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.71%
Min EPS beat(2)-2.5%
Max EPS beat(2)21.92%
EPS beat(4)3
Avg EPS beat(4)7.28%
Min EPS beat(4)-2.5%
Max EPS beat(4)21.92%
EPS beat(8)6
Avg EPS beat(8)11.32%
EPS beat(12)8
Avg EPS beat(12)8.07%
EPS beat(16)9
Avg EPS beat(16)2.46%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)187.99%
Min Revenue beat(4)-100%
Max Revenue beat(4)1051.96%
Revenue beat(8)1
Avg Revenue beat(8)46.88%
Revenue beat(12)2
Avg Revenue beat(12)393.89%
Revenue beat(16)2
Avg Revenue beat(16)270.42%
PT rev (1m)0%
PT rev (3m)-6.56%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.83%
EPS NY rev (1m)6.93%
EPS NY rev (3m)19.55%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)109.54%
Revenue NY rev (3m)10.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1436.89
P/FCF N/A
P/OCF N/A
P/B 4.82
P/tB 4.82
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.78
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -66.12%
ROE -91.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.74%
ROA(5y)-45.27%
ROE(3y)-70.15%
ROE(5y)-58.52%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 9.18%
Cap/Sales 27.66%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.48
Quick Ratio 5.48
Altman-Z -1.72
F-Score1
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)476.17%
Cap/Depr(5y)300.89%
Cap/Sales(3y)412.5%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%26.09%
EPS Next Y23.5%
EPS Next 2Y18.72%
EPS Next 3Y30.51%
EPS Next 5Y41.82%
Revenue 1Y (TTM)-33.43%
Revenue growth 3YN/A
Revenue growth 5Y-11.05%
Sales Q2Q%-100%
Revenue Next Year1598.99%
Revenue Next 2Y1408.36%
Revenue Next 3Y782.06%
Revenue Next 5Y383.55%
EBIT growth 1Y-23.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.51%
EBIT Next 3Y22.13%
EBIT Next 5Y32.89%
FCF growth 1Y-84.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.06%
OCF growth 3YN/A
OCF growth 5YN/A